Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma

被引：0

作者：

Elias, Alexandra ^{[1
]}

Marques-Piubelli, Mario L. ^{[2
]}

Nair, Ranjit ^{[3
]}

Prakash, Rishab ^{[4
]}

Ahmed, Sairah ^{[4
]}

Malpica, Luis

Lee, Hun Ju ^{[4
]}

Xu, Jie ^{[6
]}

Flowers, Christopher R. ^{[4
]}

Neelapu, Sattva S. ^{[4
,6
]}

Vega, Francisco

Miranda, Roberto ^{[6
]}

Iyer, Swami P. ^{[5
]}

机构：

[1] McGovern Med Sch, Houston, TX USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Pearland, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[5] Univ Texas MD Anderson Canc Ctr, Lymphoma & Myeloma, Houston, TX USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-187939

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.
Jagadeesh, Deepa
Horwitz, Steven M.
Bartlett, Nancy L.
Advani, Ranjana H.
Jacobsen, Eric D.
Duvic, Madeleine
Gautam, Ashish
Rao, Shangbang
Onsum, Matthew
Fanale, Michelle
Kim, Youn H.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[32] Brentuximab vedotinRecurrent anaplastic large cell lymphoma with loss of CD30 expression: case report
Reactions Weekly, 2017, 1657 (1) : 91 - 91
[33] Alternate dosing regimens of brentuximab vedotin for CD30+cutaneous T-cell lymphoma
Lewis, D. J.
Kim, Y. H.
Duvic, M.
BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (01) : 302 - 303
[34] Brentuximab Vedotin in primary cutaneous CD30+large-cell anaplastic T-Cell Lymphoma
Moritz, R. K. C.
Patsinakidis, N.
Terras, S.
Moellenhoff, K.
Gambichler, T.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (09): : 921 - 921
[35] CD30 Expression by B and T Cells A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified
Onaindia, Arantza
Martinez, Nerea
Montes-Moreno, Santiago
Almaraz, Carmen
Rodriguez-Pinilla, Socorro M.
Cereceda, Laura
Revert, Jose B.
Ortega, Cesar
Tardio, Antoni
Gonzalez, Lucia
Garcia, Sonia
Camacho, Francisca I.
Gonzalez-Vela, Carmen
Piris, Miguel A.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (03) : 378 - 385
[36] Brentuximab vedotin in T-cell lymphoma
Van der Weyden, Carrie
Dickinson, Michael
Whisstock, James
Prince, H. Miles
EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (01) : 5 - 19
[37] Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression
Saintes, C.
Saint-Jean, M.
Renaut, J. J.
Dreno, B.
Quereux, G.
BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (03) : 819 - 821
[38] CD30 Expression and Prognostic Significance in R-EPOCH-Treated Patients with Diffuse Large B-Cell Lymphoma
Xu, Jie
Oki, Yasuhiro
Saksena, Annapurna
Desai, Parth
Lin, Pei
Tang, Guilin
Yin, C. Cameron
You, M. James
Thakral, Beenu
Medeiros, L. Jeffrey
Li, Shaoying
HUMAN PATHOLOGY, 2017, 60 : 160 - 166
[39] Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry
Bartlett, Nancy L.
Smith, Mitchell R.
Siddiqi, Tanya
Advani, Ranjana H.
O'Connor, Owen A.
Sharman, Jeff P.
Feldman, Tatyana
Savage, Kerry J.
Shustov, Andrei R.
Diefenbach, Catherine S.
Oki, Yasuhiro
Palanca-Wessels, Maria Corinna
Uttarwar, Mayur
Li, Martha
Yang, Jing
Jacobsen, Eric D.
LEUKEMIA & LYMPHOMA, 2017, 58 (07) : 1607 - 1616
[40] PERSISTENCE OF CD30 EXPRESSION IN CD30-POSITIVE LYMPHOMAS FOLLOWING TREATMENT WITH BRENTUXIMAB VEDOTIN (SGN-35)
Chen, W.
Nathwani, N.
Forman, S.
Popplewell, L.
Krishnan, A.
Gomez, C.
Karanes, C.
Smith, E.
Farol, L.
Thomas, S.
Kim, Y.
HAEMATOLOGICA, 2012, 97 : 81 - 82

← 1 2 3 4 5 →